Cancer: Biomarkers, the Path from a Molecular Clue to Clinical Application
DOI:
https://doi.org/10.20983/culcyt.2026.3.5.1Keywords:
cancer, biomarker, validationAbstract
Cancer represents a public health concern, accounting for thousands of new cases and deaths; that’s why considerable efforts have been devoted to identifying complementary tools, looking for new procedures and changing the conventional medical evaluation and diagnosis. Biomarkers could be one of these tools and provide valuable information about health or disease status. However, before to the clinical practice, these must be rigorously validated ensuring their accuracy, reproducibility, and reliability.
Downloads
References
World Health Organization, “Global status report on cancer 2026: The future we choose together”, World Health Organization Ginebra, Suiza, 2026. [En línea] Disponible: https://www.who.int/publications/i/item/9789240123977
National Cancer Institute. “Understanding cancer”. Cancer.gov. [En línea]. Disponible: https://www.cancer.gov/about-cancer/understanding
A. B. Chen et al., “Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study”, J. Clin. Oncol., vol. 31, n.º 5, pp. 558-564, feb. 2013, doi: 10.1200/jco.2012.43.7954.
A. P. S. Sandhu et al., “Decoding cancer risk: Understanding gene-environment interactions in cancer development”, Cureus, vol. 16, n.º 7, art. e64936, jul. 2024, doi: 10.7759/cureus.64936.
S. Das, M. K. Dey, R. Devireddy y M. R. Gartia, “Biomarkers in cancer detection, diagnosis y prognosis”, Sensors, vol. 24, n.º 1, art. 37, 2024, doi: 10.3390/s24010037.
K. Purkayastha et al., “The issues and challenges with cancer biomarkers”, J Cancer Res Ther, vol. 19, supl. 1, pp. S20-S35, 2023, doi: 10.4103/jcrt.jcrt_384_22.
N. H. Esfandari y M. Papaleontiou, “Biochemical testing in thyroid disorders”, Endocrinol Metab Clin North Am, vol. 46, n.º 3, pp. 631-648, sept. 2017, doi: 10.1016/j.ecl.2017.04.002.
D. B. Sacks et al., “Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus”, Diabetes Care, vol. 46, n.º 10, pp. e151-e199, 2023, doi: 10.2337/dci23-0036.
S. A. Butler, S. A. Khanlian y L. A. Cole, “Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices”, Clinical Chemistry, vol. 47, n.º 12, pp. 2131-2136, 2001, doi: 10.1083/clinchem/47.12.2131.
M.Partidar, S. Agrawal, F. Parveen y P. Khare, “Molecular insights of saliva in solving paternity dispute”, J. Forensic Dent. Sci., vol. 7, n.º 1, pp. 76-79, en.-abr. 2015, doi: 10.4103/0975-1475.150325.
K. C. Wai, M. P. Strohl, A. van Zante y P. K. Ha, “Molecular diagnosis in human papillomavirus-related head and neck squamous cell carcinoma”, Cells, vol. 9, n.º 2, art. 500, feb. 2020, doi: 10.3390/cells9020500.
J. M. Vindeirinho, E. Pinho, N. F. Azevedo y C. Almeida, “SARS-CoV-2 diagnostics based on nucleic acids amplification: From fundamental concepts to applications and beyond”, Front. Cell. Infect. Microbiol., vol. 12, art. 799678, mar. 2022, doi: 10.3389/fcimb.2022.799678.
T. Y. Jin, K. S. Park, S. E. Nam, Y. B. Yoo, W. S. Park y I. J. Yun, “BRCA1/2 serves as a biomarker for poor prognosis in breast carcinoma”, Int J Mol Sci, vol. 23, n.º 7, art. 3754, 2022, doi: 10.3390/ijms230737.
X. Cheng, “A comprehensive review of HER2 in cancer biology and therapeutics”, Genes, vol. 15, n.º 7, art. 903, 2024, doi: 10.3390/genes15070903.
B. Rovcanin, S. Damjanovic, V. Zivaljevic, A. Diklic, M. Jovanovic y I. Paunovic, “The results of molecular genetic testing for RET pro-oncogene mutations in patients with medullary thyroid carcinoma in a referral center after the two-decade period”, Hippokratia, vol. 20, n.º 3, pp. 187-191, jul.-sept. 2016.
NIH. “Pruebas de marcadores tumorales más comunes”. Cancer.gov. [En línea]. Disponible: https://cancer.gov/espanol/cancer/diagnostico-estadificacion/diagnostico/lista-marcadores-tumorales
F. Rousseau, C. Lindsay, Y. Labelle y Y. Giguere, “Measuring the chronology of the translational process of molecular genetic discoveries”, Clin Chem Lab Med, vol. 57, n.º 8, pp. 1136-1141, 2019, doi: 10.1515/cclm-2018-1126.
Z. Jiang, H. Zhang, Y. Gao y Y. Sun, “Multi-omics strategies for biomarker discovery and application in personalized oncology”, Mol Biomed, vol. 6, art. 115, nov. 2025, doi: 10.1186/s43556-025-00340-0.
F. S. Ou, S. Michiels, Y. Shyr, A. A. Adjei y A. L. Oberg, “Biomarker discovery and validation: Statistical considerations”, J Thorac Oncol, vol. 16, n.º 4, pp. 537-545, abr. 2021, doi: 10.1016/j.jtho.2021.01.1616.
M. P. Pavlov, E. P. Diamandis y I. M. Blasuting, “The long journey of cancer biomarkers from the bench to the clinic”, Clin Chem, vol. 59, n.º 1, pp. 147-157, 2013, doi: 10.1373/clinche.2012.184614.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Diana Patricia Armenta Calzadillas, Mauricio Salcedo Vargas, Florinda Jiménez Vega

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Todos los contenidos de CULCYT se distribuyen bajo una licencia de uso y distribución “Creative Commons Reconocimiento-No Comercial 4.0 Internacional” (CC-BY-NC). Puede consultar desde aquí la versión informativa de la licencia.
Los autores/as que soliciten publicar en esta revista, aceptan los términos siguientes: a) los/las autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra; y b) se permite y recomienda a los/las autores/as agregar enlaces de sus artículos en CULCYT en la página web de su institución o en la personal, debido a que ello puede generar intercambios interesantes y aumentar las citas de su obra publicada.
